Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
38 Results for "
Ikr
" in MedChemExpress (MCE) Product Catalog:
Products (38)
38 Results for "Ikr" in MCE Product Catalog:
Cat. No.: HY-106855
CAS No.: 123955-10-2
Synonyms: H 234/09
Target:
Research Areas:
Almokalant is a class III antiarrhythmic agent, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K + current.
Cat. No.: HY-101436
CAS No.: 101526-83-4
Synonyms: CK-1752
Target:
Research Areas:
Sematilide (CK-1752) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K + current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent .
Cat. No.: HY-108163
CAS No.: 179258-59-4
Target:
Research Areas:
SB-237376 (free base) is a potassium and calcium channel blocker. SB-237376 (free base) can inhibit the rapidly activating delayed rectifier potassium current I(Kr) (IC50 is 0.42 μM), and at high concentrations, it blocks the L-type calcium current I(Ca,L). In the rabbit ventricular model, SB-237376 (free base) can induce early afterdepolarizations (EADs) at a concentration of 3 µM. Compared to other IKr inhibitors such as dl-sotalol, SB-237376 has a lower proarrhythmic risk. SB-237376 (free base) holds potential for research in the field of arrhythmia-related diseases .
Cat. No.: HY-108163A
CAS No.: 179258-62-9
Target:
Research Areas:
SB-237376 is a blocker of potassium and calcium channels. SB-237376 inhibits the rapidly activating delayed rectifier potassium current I(Kr) (IC50: 0.42 μM) and blocks the L-type calcium current I(Ca,L) at high concentrations .
Cat. No.: HY-B0232R
CAS No.: 115256-11-6
Synonyms: UK 68789 (Standard)
Target:
Research Areas:
Dofetilide (Standard) is the analytical standard of Dofetilide. This product is intended for research and analytical applications. Dofetilide (UK 68789), as a class III antiarrhythmic agent, is an orally active, potent and specific IKr blocker. Dofetilide can be used for the research of cardiovascular disease .
Cat. No.: HY-B0387R
CAS No.: 122647-32-9
Synonyms: U70226E (Standard)
Target:
Research Areas:
Ibutilide (fumarate) (Standard) is the analytical standard of Ibutilide (fumarate). This product is intended for research and analytical applications. Ibutilide (U70226E) fumarate, an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K + current (IKr) in AT-1 cells .
Cat. No.: HY-B0772AR
CAS No.: 130656-51-8
Synonyms: MS-551 (Standard)
Target:
Research Areas:
Nifekalant (hydrochloride) (Standard) is the analytical standard of Nifekalant (hydrochloride). This product is intended for research and analytical applications. Nifekalant hydrochloride (MS-551), a class III antiarrhythmic agent, is a IKr potassium channel blocker with an IC50 of 10 µM. Nifekalant hydrochloride can be used for refractory ventricular tachyarrhythmias research .
Cat. No.: HY-101436AR
CAS No.: 101526-62-9
Synonyms: CK-1752 hydrochloride (Standard)
Target:
Research Areas:
Sematilide (hydrochloride) (Standard) is the analytical standard of Sematilide (hydrochloride). This product is intended for research and analytical applications. Sematilide hydrochloride (CK-1752 hydrochloride) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent .
Cat. No.: HY-B0280R
CAS No.: 95635-55-5
Synonyms: CVT 303 (Standard); RS 43285-003 (Standard)
Research Areas:
Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
Target:
Indoleamine 2,3-Dioxygenase (IDO) Calcium Channel Sodium Channel Potassium Channel Cytochrome P450
Research Areas:
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases .
Cat. No.: HY-106577R
CAS No.: 53267-01-9
Synonyms: Cifenline (Standard); Ro 22-7796 (Standard)
Target:
Research Areas:
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
Cat. No.: HY-106577S
Synonyms: Cifenline-d4; Ro 22-7796-d4
Cat. No.: HY-18600AS
Synonyms: NE-10064-d8 dihydrochloride
Cat. No.: HY-167866
CAS No.: 125279-79-0
Target:
Research Areas:
Ersentilide, a benzamide derivative, is a is a β1-adrenoceptor antagonist and Ikr blocker. Ersentilide is effective in several intact animal models of arrhythmia .
Cat. No.: HY-108586R
CAS No.: 343630-41-1
Target:
Research Areas:
NS3623 (Standard) is the analytical standard of NS3623 (HY-108586). This product is intended for research and analytical applications. NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels .
Cat. No.: HY-106577S1
Synonyms: Cifenline-d5; Ro 22-7796-d5
Cat. No.: HY-124940
CAS No.: 446877-42-5
Target:
Research Areas:
CPU-228 is a complex class III antiarrhythmic agent. CPU-228 concentration-dependently blocks the activities of the rapid component 50 of the delayed rectifier potassium channel (IKr) and the L-type calcium channel (ICa,L), with an IC50 value of 0.909 μM for ICa,L current. CPU-228 produces negative inotropic effects and induces mild, non-frequency-dependent prolongation of the effective refractory period (ERP) in isolated left atria. CPU-228 reduces the incidence of torsades de pointes (TDP) in anesthetized rabbits and inhibits ischemia/reperfusion-induced arrhythmias in rats. CPU-228 can be used in studies related to torsades de pointes .
Cat. No.: HY-189366
Target:
Research Areas:
Antiarrhythmic agent-4 is an orally active cardiac ion channel modulator. Antiarrhythmic agent-4 selectively inhibits pathological late sodium current of the cardiac NaV1.5 channel (IC50 = 2.5 μM) while blocking the hERG (IKr) channel (IC50 = 1.5 μM). Antiarrhythmic agent-4 reduces intracellular sodium/calcium overload, prolongs the cardiac action potential, and avoids conduction block and negative inotropic effects. Antiarrhythmic agent-4 exhibits antiarrhythmic efficacy in an isoproterenol-induced atrial fibrillation model in isolated rabbit hearts and improves survival and cardiac function in a Doxorubicin (HY-15142A)-induced heart failure mouse model. Antiarrhythmic agent-4 can be used for research on atrial fibrillation and heart failure .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
